Reducing the Effects of Malaria in Children by Administering Repeated Preventive Doses
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The general goal of the project is to assess the infectious status and immunity of mothers
and children living in a malaria region. A major part of the study involves administering an
effective antimalarial, sulfadoxine-pyrimethamine (Fansidar®), to children at the same
timepoints as vaccinations, i.e. at age 3, 9 and 15 months. The main objective is to study
safety, efficacy, and consequences of such a strategy in particular the ability to reduce the
risk of anemia.
Phase:
Phase 4
Details
Lead Sponsor:
Albert Schweitzer Hospital
Collaborators:
Bill and Melinda Gates Foundation Bundesministerium fuer Bildung und Forschung (BMBF) Deutscher Akademischer Austausch Dienst German Research Foundation Medical Research Unit, Lambarene
Treatments:
Fanasil, pyrimethamine drug combination Pyrimethamine Sulfadoxine